Agendia's Pipeline, Test Business Could Benefit From Companion-Dx Deal with AstraZeneca, NKI
May 24, 2011
Agendia's Pipeline, Test Business Could Benefit From Companion-Dx Deal with AstraZeneca, NKI
CEO Bernhard Sixt said the collaboration may "benefit" ColoPrint, Agendia's in-development colorectal cancer test, by helping to discover a "tentative molecular subtype signature for the test."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- After Decade as CRO, Shanghai Biochip Plans Move into Chinese Molecular Dx Market
December 18, 2012 / BioArray News - Agendia Enters Companion Dx Arena via Collaboration with AstraZeneca, Netherlands Cancer Institute
May 11, 2011 / Pharmacogenomics Reporter - 'Provocative' Paper Sparks Debate on Relevance of Breast Cancer Gene Expression Signatures
September 4, 2012 / BioArray News - Agendia Gets FDA Clearance for MammaPrint on Agilent Systems
February 23, 2011 / GenomeWeb Daily News - Agendia Moving to Larger Lab to Keep Pace with Growing MammaPrint Testing Volume
August 11, 2010 / Pharmacogenomics Reporter